<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183686</url>
  </required_header>
  <id_info>
    <org_study_id>ID-087-101</org_study_id>
    <nct_id>NCT04183686</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects</brief_title>
  <official_title>Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects, Including Food Effect, Mass Balance, and Metabolite Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine the safety, tolerability, and pharmacokinetics of single- and
      multiple-ascending doses of ACT-1014-6470 in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">July 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single-center, double-blind, randomized, placebo-controlled Phase 1 study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf)</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD, Day 1 to Day 8 for ADME cohort A4) and from Day 1 to Day X+3 of Part B (MAD, with Day X = day of last study treatment administration).</description>
  </primary_outcome>
  <other_outcome>
    <measure>All cohorts: Maximum plasma concentration (Cmax).</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD, Day 1 to Day 8 for ADME cohort A4) and from Day 1 to Day X+3 of Part B (MAD, with Day X = day of last study treatment administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>All cohorts: Time to reach Cmax (tmax).</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD, Day 1 to Day 8 for ADME cohort A4) and from Day 1 to Day X+3 of Part B (MAD, with Day X = day of last study treatment administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>All cohorts: t½.</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD, Day 1 to Day 8 for ADME cohort A4) and from Day 1 to Day X+3 of Part B (MAD, with Day X = day of last study treatment administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>Food effect evaluation only: AUC0-inf under fasted conditions.</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Food effect evaluation only: Cmax under fasted conditions.</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Food effect evaluation only: tmax under fasted conditions.</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Food effect evaluation only: t½ under fasted conditions</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day 4 of Part A (SAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose.</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>Blood samples for determination of PK parameters will be collected at predefined time points from Day 1 to Day X+3 of Part B (MAD, with Day X = day of last study treatment administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse events (AEs)</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>From start of study treatment administration up to End-of-Study (EOS) or End-of-Period (EOP). - Treatment-emergent serious AEs from the start of the study treatment administration up to EOS or EOP.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>Total duration of assessments: up to 3 weeks.</time_frame>
    <description>From start of study treatment administration up to End-of-Study (EOS) or End-of-Period (EOP). - Treatment-emergent serious AEs from the start of the study treatment administration up to EOS or EOP.</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A1 of ACT-1014-6470; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A2 of ACT-1014-6470; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A4 of ACT-1014-6470; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A5 of ACT-1014-6470; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A (SAD): Dose A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose A6 of ACT-1014-6470; soft capsule for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): Dose B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): Dose B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): Dose B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (MAD): Dose B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-1014-6470 (SAD)</intervention_name>
    <description>Single dose of ACT-1014-6470; soft capsules for oral use.</description>
    <arm_group_label>Part A (SAD): Dose A1</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A2</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A3</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A4</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A5</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-1014-6470 (MAD)</intervention_name>
    <description>Multiple doses of ACT-1014-6470; soft capsules for oral use.</description>
    <arm_group_label>Part B (MAD): Dose B1</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B2</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B3</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (SAD)</intervention_name>
    <description>Single dose of matching placebo; soft capsules for oral use.</description>
    <arm_group_label>Part A (SAD): Dose A1</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A2</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A3</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A4</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A5</arm_group_label>
    <arm_group_label>Part A (SAD): Dose A6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (MAD)</intervention_name>
    <description>Multiple doses of matching placebo; soft capsules for oral use.</description>
    <arm_group_label>Part B (MAD): Dose B1</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B2</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B3</arm_group_label>
    <arm_group_label>Part B (MAD): Dose B4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-ACT-1014-6470 microtracer</intervention_name>
    <description>Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.</description>
    <arm_group_label>Part A (SAD): Dose A4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-ACT-1014-6470 microtracer placebo</intervention_name>
    <description>Single dose of matching placebo; soft capsules for oral use.</description>
    <arm_group_label>Part A (SAD): Dose A4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure.

          -  Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years
             (inclusive) at Screening.

          -  Healthy on the basis of medical history, physical examination, cardiovascular
             assessments, and clinical laboratory tests.

          -  Male subjects with a partner who might become pregnant must either be vasectomized or
             agree to practice adequate contraception from admission to the study site until 3
             months after dosing, or the partner must consistently and correctly use a highly
             effective method of contraception.

        Inclusion Criteria for Part B:

          -  Women of childbearing potential must have a negative serum pregnancy test at Screening
             and a negative urine pregnancy test on Day -1. They must consistently and correctly
             use a highly effective method of contraception with a failure rate of &lt; 1% per year,
             be sexually inactive, or have a vasectomized partner.

          -  Women of non-childbearing potential must have a negative serum pregnancy test at
             Screening and a negative urine pregnancy test on Day -1.

        General Exclusion Criteria:

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition, which, in the opinion of the investigator, are likely to interfere
             with the absorption, distribution, metabolism, or excretion of the study treatment.

        Exclusion Criteria for the ADME evaluation (Part A) only:

          -  Radiation exposure, excluding background radiation but including diagnostic X-rays and
             other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5
             years. Occupationally exposed workers, as defined in the relevant Ionising Radiation
             Regulations, must not participate in the study.

          -  Participation in any study involving administration of any 14C radiolabeled compound
             within the 12 months prior to Screening.

        Exclusion Criteria for Part B:

        - Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

